SXTC - China SXT Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5315
+0.0261 (+5.16%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.5054
Open0.4990
Bid0.5277 x 1200
Ask0.5335 x 1300
Day's Range0.4821 - 0.5380
52 Week Range0.3400 - 3.2800
Volume5,056,016
Avg. Volume5,654,662
Market Cap14.737M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0820
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
68% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hedge Funds Warming Up To China SXT Pharmaceuticals, Inc. (SXTC)
    Insider Monkey

    Hedge Funds Warming Up To China SXT Pharmaceuticals, Inc. (SXTC)

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

  • China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government
    PR Newswire

    China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government

    China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that a fund granted to the Company for the key techniques incorporated into advanced Directly-Oral TCMPs derived from agriculture has been approved on February 19, 2020, by the Hailing District Science and Technology Bureau of Taizhou city.

  • How Does China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Compare To Its Industry, After Its Big Share Price Gain?
    Simply Wall St.

    How Does China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Compare To Its Industry, After Its Big Share Price Gain?

    China SXT Pharmaceuticals (NASDAQ:SXTC) shares have had a really impressive month, gaining 45%, after some slippage...

  • China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory
    PR Newswire

    China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory

    China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that its DNA Exam Laboratory completely built in October of 2019 recently has been approved by Jiangsu province Drug Administration (JSDA). The Laboratory has been granted to perform research and development (R&D;) and quality control of TCM raw materials and TCMP products applying DNA testing technology.

  • China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
    PR Newswire

    China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

    China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC) announced today that on December 27, 2019 the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share for its common shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2).

  • What Is China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Ratio After Its Share Price Tanked?
    Simply Wall St.

    What Is China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Ratio After Its Share Price Tanked?

    To the annoyance of some shareholders, China SXT Pharmaceuticals (NASDAQ:SXTC) shares are down a considerable 31% in...

  • Should You Worry About China SXT Pharmaceuticals, Inc.’s (NASDAQ:SXTC) ROCE?
    Simply Wall St.

    Should You Worry About China SXT Pharmaceuticals, Inc.’s (NASDAQ:SXTC) ROCE?

    Today we are going to look at China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) to see whether it might be an attractive...

  • PR Newswire

    China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques

    TAIZHOU, China, Sept. 11, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, ...

  • PR Newswire

    China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019

    TAIZHOU, China, Aug. 19, 2019 /PR Newswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), today announced that its Annual Report on From 20-F for the fiscal year ended March 31, 2019 has been filed with the U.S. Securities and Exchange Commission (the "SEC") on August 15, 2019. An electronic copy of the annual report on Form 20-F can be accessed on China SXT's website at http://www.sxtchina.com and on the SEC's website at www.sec.gov. Shareholders may receive a hard copy of China SXT's audited financial statement for the fiscal year ended March 31, 2019 free of charge upon request.

  • PR Newswire

    China SXT Pharmaceuticals, Inc. Receives New Pharmaceutical GMP Certificate

    TAIZHOU, China, Aug. 12, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today that it has been issued a new Certificate of GMP (Good Manufacturing Practice) for Pharmaceutical Products (the "Certificate") by the Food and Drug Administration of Jiangsu Province, China ("FDA"). The FDA staff conducted its on-site examination in accordance with government regulations.